KYTHERA Biopharmaceuticals Announces Limited Lock-up Release Of Shares For Charitable Donation

KYTHERA Biopharmaceuticals, Inc. (NASDAQ: KYTH) announced today that J.P. Morgan Securities LLC and Goldman, Sachs & Co., the lead book-running managers in the Company’s recent public sale of 5,060,000 shares of common stock, are releasing a lock-up restriction with respect to 7,563 shares of the Company’s common stock held by Keith Leonard, President and Chief Executive Officer of the Company, to allow Mr. Leonard to make a charitable donation to a not-for-profit entity. The release will take effect on December 21, and the shares will be transferred to the not-for-profit entity and may be sold by that entity on or after such date.

This press release is not an offer for sale of the securities in the United States or in any other jurisdiction where such offer is prohibited, and such securities may not be offered or sold in the United States absent registration or an exemption from registration under the United States Securities Act of 1933, as amended.

About KYTHERA Biopharmaceuticals, Inc.

KYTHERA Biopharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel prescription products for the aesthetic medicine market. KYTHERA’s product candidate, ATX-101, is a potential first-in-class, injectable treatment currently in Phase III clinical development for the reduction of submental fat, which commonly presents as an undesirable “double chin.” KYTHERA also maintains an active research interest in hair and fat biology, pigmentation modulation and facial contouring. Find more information at http://www.kytherabiopharma.com.

Copyright Business Wire 2010

If you liked this article you might like

The Nominees for Best Biopharma CEO of 2015 Are...

The Nominees for Best Biopharma CEO of 2015 Are...

Jim Cramer -- Valeant's Sales Struggles Mean Allergan Could Profit

Jim Cramer -- Valeant's Sales Struggles Mean Allergan Could Profit

Pfizer's Bid for Allergan May Be Too Good to Turn Down

Pfizer's Bid for Allergan May Be Too Good to Turn Down

Allergan Beats Earnings, Delays Forecast Until Next Quarter

Allergan Beats Earnings, Delays Forecast Until Next Quarter

Allergan Beats Estimates, Company to Update Guidance Next Quarter

Allergan Beats Estimates, Company to Update Guidance Next Quarter